Kezar Life Sciences reports preliminary cash of $132.2M as of Dec 31, 2024

Kezar Life Sciences, Inc.

Preliminary cash, equivalents, and marketable securities at $132.2M as of December 31, 2024.
Shares outstanding of 7.3 million as of December 31, 2024.
Estimates are unaudited, subject to year-end closing adjustments; not a comprehensive financial statement.

item 2.02

Kezar Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001645666-25-000001

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.